Get the Stockscreener App
4.49
16.07%
-0.86
Evotec Se Adr stock is traded at $4.49, with a volume of 636.39K.
It is down -16.07% in the last 24 hours and up +37.31% over the past month.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
See More
Previous Close:
$5.35
Open:
$4.37
24h Volume:
636.39K
Relative Volume:
3.42
Market Cap:
$1.59B
Revenue:
$842.96M
Net Income/Loss:
$-185.63M
P/E Ratio:
-13.15
EPS:
-0.3415
Net Cash Flow:
$-228.52M
1W Performance:
-17.46%
1M Performance:
+37.31%
6M Performance:
-13.15%
1Y Performance:
-56.53%
1-Day Range:
$4.2814
$4.50
1-Week Range:
$4.2814
$5.63
52-Week Range:
$2.85
$12.00
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| EVO | 4.49 | 1.59B | 842.96M | -185.63M | -228.52M | -0.3415 |
| ZTS | 176.96 | 79.73B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.65 | 43.70B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.38 | 42.47B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.12 | 19.40B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.37 | 15.88B | 15.05B | -883.30M | 1.89B | 1.53 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec Se Adr Stock (EVO) Latest News
Evotec SE withdraws acquisition offer - Investing.com
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Evotec SE responds to media speculation - Investing.com India
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec SE responds to media speculation By Investing.com - Investing.com UK
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal - Benzinga
Earnings call: Evotec SE maintains 2024 outlook amid strategic changes - Investing.com India
Evotec SE ADR earnings beat by $0.02, revenue fell short of estimates - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Stock Information - Evotec
Annual General Meeting - Evotec
Investor Relations - Evotec
Earnings call: Evotec SE reports revenue increase, plans cost cuts - Investing.com
Earnings call: Evotec SE revises 2024 outlook amid market challenges By Investing.com - Investing.com Canada
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths - Yahoo Finance
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
Antibody Discovery Market Size Expected to Surge to USD 4.8 - GlobeNewswire Inc.
Evotec stock holds Buy rating with price target from TD Cowen By Investing.com - Investing.com India
Evotec (OTCMKTS:EVTCY) Sets New 52-Week Low at $4.65 - Defense World
Financial Metrics Check: Evotec SE ADR (EVO)'s Ratios for Trailing Twelve Months – DWinneX - The Dwinnex
Healthcare Sector - Morningstar
Ratio Examination: Evotec SE ADR (EVO)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Evotec's Underlying Demand Looks Stable as Momentum Builds, but Some Market Challenges Linger - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges By Investing.com - Investing.com
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com Canada
Evotec gains R&D license from Centogene for Gaucher disease - Investing.com India
Closing Bell Recap: Evotec SE ADR (EVO) Ends at 5.23, Reflecting a -31.63 Downturn – DWinneX - The Dwinnex
QT to end this December with hardly a whimper: Barclays By Investing.com - Investing.com
Dow Dips Over 100 Points; Ribbon Communications Shares Spike Higher By Benzinga - Investing.com UK
Evotec and Variant Bio partner to develop fibrosis treatments By Investing.com - Investing.com
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Germany stocks mixed at close of trade; DAX down 0.03% By Investing.com - Investing.com
Germany stocks mixed at close of trade; DAX down 0.30% By Investing.com - Investing.com
Evotec: R&D, Customer Growth Not Enough To Offset Headwinds - Seeking Alpha
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus - The Globe and Mail
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Evotec SEADR Shares Near 52-Week LowMarket Mover - Nasdaq
A Peek Into The Markets: US Stock Futures Rise; J&J Secures Emergency Authorization for Covid-19 Vaccine - Benzinga
Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare ConferenceSlideshow (NASDAQ:EVO) - Seeking Alpha
Together for Medicines That MatterEvotec Website (English) - Evotec
Evotech and Roche subsidiary Genentech enter into drug discovery alliance - Proactive Investors USA
Evotec Se Adr Stock (EVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):